Jasper Therapeutics announces positive Phase 1b data for briquilimab in Fanconi Anemia; all 3 patients engrafted

Jasper Therapeutics, Inc.

All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recovery.
Briquilimab was well tolerated without any complications; no briquilimab-related adverse events or toxicities.
Study expansion to Phase 2a is ongoing, led by Stanford.
Data to be presented at 2023 Fanconi Anemia Research Fund Scientific Symposium (Sept 28-Oct 1).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.